Novavax Inc. (NVAX)

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the o...

The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.

Live Updates Live Coverage Has Ended Jamie Dimon on the Risk of Inflation and Deflation 3:23 pm by Gerelyn Terzo The markets have recouped most of their losses, with the SPX now down a modest 0.03%. J...

U.S. equities were down at midday, while the yield on the 10-year Treasury jumped, as the market reacted to Moody's downgrading the U.S. debt rating. The Dow Jones Industrial Average, S&P 500, and Nas...

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.

Biotech stock Novavax Inc (NASDAQ:NVAX) is skyrocketing today, up 26% at $8.48 at last glance, after the U.S. Food & Drug Administration (FDA) approved the company's COVID-19 vaccine.